Healthcare Global Enterprises Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Radiation downtime drove the miss: Over 300 lost LINAC operating days shaved ~1% of total revenue from the high-margin radiation segment, compressing adjusted EBITDA margin from ~19% to ~16% sequentially.
• Recovery is already in motion: Four of the five delayed LINACs became operational during Q2, and June numbers were described as "very promising," setting up a bounce-back quarter.
• Acquisitions are accelerating consolidation: HCG closed the Indore acquisition and simplified the Nagpur structure, both now 100% owned, and signaled more deals are in active negotiation.
• Talent investment is front-loaded: Clinical hires in competitive markets like Mumbai came at a premium, but management says the buildout is substantially done and the cost-to-revenue ratio will normalize as those doctors ramp up.
• What to watch next quarter: Whether the LINAC normalization delivers the promised margin bounce, the pace of revenue ramp at Kolkata and South Mumbai, and any new acquisition announcements.

The LINAC Disruption and Margin Walk

• What broke: Five LINAC installations or upgrades were delayed in Q1, three of them replacements, costing the network more than 300 operating days on radiotherapy. Radiation oncology carries an ~80% contribution margin, so even a small revenue shift hurts disproportionately.
• The math: Radiation fell from 18% to 17% of total business, a ~₹4.5 crores revenue drop that flowed almost entirely to the EBITDA line and was the single largest driver of the margin decline.
• Annual wage cycle compounded it: Salary increments effective April added the usual Q1 margin headwind, and the combination of lost high-margin volume plus fixed-cost step-up produced the ~300 bps sequential EBITDA margin drop.
• Normalization timeline: Four of the five LINACs were operational by early Q2, and management stated the impact is behind them. The fifth was not flagged as a continuing concern.

Raj Gore: "So we are now not going to see any impact in the second quarter. And certainly, the numbers what we have seen in June are very promising. So we should be able to reach our expected level in the second quarter."

Acquisition Strategy and Central India Buildout

• Indore entry: HCG acquired SRJ CBCC Hospital, a 50-bed comprehensive cancer center scalable to 100 beds, with medical, surgical and radiation oncology. The center is the largest private cancer player in Indore, holds a top-three position across all modalities, and carries no scheme business, only cash and TPA.
• Nagpur simplified: HCG acquired the partner's 26% stake in the infrastructure entity, consolidating both Nagpur operations to 100% ownership and unwinding a complex structural arrangement. Nagpur is described as a strategic market in Central India.
• More deals in pipeline: Management confirmed it is "in the middle of doing some more deals" and declined to disclose Indore's individual center EBITDA, citing the need to protect negotiating position on active transactions.
• Acquisition guardrails: All deals must be at least at par accretive to return on capital employed. No greenfield projects are planned; expansion is limited to acquiring revenue-and-EBITDA-positive hospitals or expanding existing mature facilities like the Whitefield COE.
• Central India hub-and-spoke: The Indore and Nagpur assets form the base for a hub-and-spoke growth model in the region, with plans to add another center in Indore within two years.

Management: "The company is also in the middle of doing some more deals. So, right now, we are not in a position to sort of disclose some of those parameters as it may compromise our position in the deals."

Emerging Centers: Investment Phase Versus Maturity

• Kolkata and South Mumbai strategy: These two newest centers are being run for revenue growth, not near-term margins. Management is "happy with the revenue growth" and expects EBITDA breakeven only in Q4 of this fiscal year.
• Clinical talent at a premium: The Mumbai buildout required hiring senior clinicians like Dr. Sachin Trivedi and Dr. Viji Krishnamurti at above-normal cost, reflecting the competitive market. Management frames this as a one-time investment, with the doctor payout-to-revenue ratio set to normalize as patient volumes build.
• Emerging center investment largely done: 80-90% of the clinical talent and market-making investment across emerging centers is complete. The margin story from here is operating leverage as revenue scales against a now mostly fixed cost base.
• Chemo growth shifting: The earlier chemo session growth surge came from ramping emerging centers like Jaipur and Nagpur. That has normalized, and incremental volume growth is now expected from Kolkata and Mumbai.
• Mature hospital expansion: Expansion plans for mature hospitals are charted, with Ahmedabad Phase 2 (₹85 crores capex, Q1 FY25) and Whitefield (₹25 crores capex, Q3 FY25) on track. Management expects operating leverage to drive margin expansion from these assets and will guide investors on details "at the appropriate time."

B.S. Ajai Kumar: "We are happy with the revenue growth which is coming in, and we do believe that EBITDA margins will play out in the future quarters."

Revenue Drivers and Mix Shifts

• Emerging centers led growth: Revenue growth was propelled by 22% YoY growth in emerging centers, with record quarterly revenues in medical value travel and digital channels.
• Chemo pricing and mix: Annual inflationary price increases of 4-5% are flowing through, and adoption of high-end molecules and immunotherapy is lifting average realization per session.
• Scheme patient exposure: Scheme patients are distributed across modalities similarly to the overall mix, with a slight skew toward chemotherapy in Tier 2 centers where late-stage patients predominantly undergo medical oncology. BPL and state schemes together account for roughly 20% of revenue, though management did not provide a target mix.
• Immunotherapy adoption: States like Orissa, Gujarat and Maharashtra are beginning to recognize targeted therapy, but patented immunotherapy drugs remain expensive and state adoption will be gradual. Management expects generics to eventually make the case easier for government approval.
• Milann drag: A slight revenue drop in the Milann fertility business was attributed to regulatory delays on surrogacy approvals by government authorities.

B.S. Ajai Kumar: "The immunotherapy drugs or patented drugs they are quite expensive... So they will have a final say, yes or no. But in the long run, I think states will have to recognize."

Balance Sheet and Capital Allocation

• Debt guardrails: Management targets a net debt-to-EBITDA range of 2 to 2.5x and expects most capex to be self-funded from internal accruals. Debt will be taken on only for acquisitions, which are expected to be both revenue and EBITDA accretive.
• Capex visibility: The two committed expansion projects total ₹110 crores. Beyond that, management is evaluating LINAC additions at three well-performing radiation centers (Kolkata, Nagpur, Vizag), likely beginning next fiscal year.
• No greenfield risk: Management explicitly ruled out greenfield projects. The Whitefield expansion is characterized as an extension of Bangalore dominance, not a true greenfield, and all future additions will be acquisitions of cash-flow-positive hospitals.
• CVC overhang: When asked about the private equity sponsor's exit timeline, the Chairman deflected, stating investors should ask CVC directly and noting only that "CVC said that they are there for long term and they may exit whenever time they think is appropriate."

Guidance and Commitments

Key Metrics